We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Legislation (77)
- Advertising (25)
- Manufacturing (19)
- Labelling and packaging (16)
- Vaping hub (13)
- COVID-19 (11)
- Compliance and enforcement (6)
- Scheduling (national classification system) (6)
- Import and export (2)
- Clinical trials (1)
- Committees and advisory bodies (1)
- Medicinal cannabis hub (1)
- Sunscreens (1)
- Urogynaecological (transvaginal) surgical mesh hub (1)
Search
195 result(s) found, displaying 126 to 150
-
Regulatory decision noticesThe Therapeutic Goods (Permissible Ingredients) Determination has been updated.
-
Regulatory decision noticesGuidance to assist sponsors when using the code tables for GMP Clearance applications
-
Regulatory decision noticesInformation to assist overseas manufactures who may undergo a remote Good Manufacturing Practice inspection during the COVID-19 pandemic
-
Regulatory decision noticesThe Therapeutic Goods (Permissible Ingredients) Determination has been updated.
-
Regulatory decision noticesInformation on an exemption for radiopharmaceuticals that facilitates interstate supply during COVID-19
-
Regulatory decision noticesListed medicine ingredients and requirements have been updated.
-
Regulatory decision noticesOn 20 November 2019 the TGA issued a direction notice to Cat Media concerning its advertising of Fatblaster Clinical
-
Regulatory decision noticesA new S41BD(3) instrument has been signed to declare that some nappy rash products are not to be medical devices for the purposes of the Act
-
Regulatory decision noticesThe Permissible Ingredients Determination has been updated.
-
Regulatory decision noticesNew requirements for listed medicines containing Andrographis paniculata
-
Regulatory decision noticesThe Permissible Ingredients Determination has been updated.
-
Regulatory decision noticesThe Therapeutic Goods (Permissible Indications) Determination has been updated
-
Regulatory decision noticesTherapeutic Goods (Declared Goods) Order 2019 consolidates and replaces several instruments
-
Regulatory decision noticesJapan has recently been added to the list of Foreign Countries and Jurisdictions determined to be comparable overseas regulators
-
Regulatory decision noticesNew requirements for caffeine and caffeine-containing ingredients within listed medicines
-
Regulatory decision noticesAn amendment to the Therapeutic Goods (Permissible Ingredients) Determination commenced on 2 September 2019.
-
Regulatory decision noticesDirection Notice issued to cease advertising of therapeutic goods not entered in the ARTG
-
Regulatory decision noticesDirection Notice issued to cease advertising of unregistered therapeutic goods to consumers
-
Regulatory decision noticesThe Therapeutic Goods (Permissible Ingredients) Determination has been updated.
-
Regulatory decision noticesDirection Notice issued to cease advertisement of prescription and illegal products
-
Regulatory decision noticesTGO 100 has been registered on the Federal Register of Legislation. It commences on 8 December 2018, repealing and replacing TGO 98
-
Regulatory decision noticesTGA issues advertising direction
-
Regulatory decision noticesThis instrument applies to an application to list a complementary medicine under section 26AE of the Act.
-
Regulatory decision noticesThis instrument applies to an application to list a medicine under section 26 or 26A of the Act.
-
Regulatory decision noticesThis instrument applies to an application to register a complementary medicine